Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Pancreatic Neoplasms 3Melanoma 2Breast Neoplasms 2Prostatic Neoplasms 1Prostate Cancer Recurrent 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neoplasm, Residual 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Magnetic Resonance Spectroscopy 49enzalutamide 46apalutamide 36Specimen Handling 34Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 27Prednisone 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 20Radiotherapy 19Biopsy 17Leuprolide 15relugolix 11gallium 68 PSMA-11 11acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11Standard of Care 10Nivolumab 10cabazitaxel 9X-Rays 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Hydroxychloroquine × 90 days × Clear all
NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡